ULS entered earnings week under scrutiny. It left it having rewritten the narrative entirely.
Q1 results landed on May 5 and they were unambiguous. Adjusted EPS of $0.50 cleared the $0.41 consensus by 22%. Revenue of $758m beat estimates by nearly $10m. The company reiterated full-year 2026 guidance for mid-single-digit organic revenue growth. The stock responded by adding 16% on the day and closing a two-day stretch at $104.74 — up 19% on the week and 24% on the month.
The clearest read on positioning going into the print was that short sellers got caught leaning the wrong way. Short interest had climbed to roughly 4.2m shares — close to 6.5% of the float — through mid-April before beginning a slow retreat. By the time the beat landed, shorts had already trimmed back to 2.8m shares, or around 4.4% of the float. The week of the earnings saw a further 1.8% daily drop on May 5, with the 30-day decline now running at 22%. That is an exit, not a rotation. Borrow costs remain negligible at 0.5% — there is no squeeze pressure here, just short sellers reducing exposure after being wrong-footed on the fundamentals. Availability is ample, meaning fresh shorts face no friction entering if sentiment turns, but none of the borrow dynamics suggest new pressure is building.
Options positioning heading into results was notably defensive and, in hindsight, excessively so. The put/call ratio ran above 2.4 all week — well above its 20-day average of 1.87 and close to the upper end of its year-long range. That hedging posture reflected genuine uncertainty before a result that cleared the bar with room to spare. Post-print, the PCR remains elevated near 2.43, which is worth noting: even after a 19% weekly move, options traders have not rotated decisively into calls. The caution has not fully cleared.
Two analysts moved targets immediately after the result. Wells Fargo's Jason Haas — who has been consistently Overweight — raised his target from $102 to $120. UBS lifted from $90 to $110 while holding Neutral. Both moves came within 24 hours of the print. The mean Street target now sits around $103, which the stock has already surpassed. That target-price overhang is the live tension: the Street's consensus has been lapped by the price. Bulls — and Wells Fargo's $120 target represents the high end of current published estimates — point to ULS's position as a global leader in testing, inspection, and certification, a structurally sticky business with pricing power. Bears flag regulatory-framework risk and roughly 24% China revenue exposure as the two variables most capable of disrupting the model. Both arguments remain active. Factor scores add a further dimension: EPS momentum ranks in the 88th percentile on a 30-day basis and 82nd on 90 days. The forward EPS growth estimate ranks in the 89th percentile. Dividend quality scores in the 91st percentile. These are not the numbers of a company under fundamental stress.
Institutional flows add a quietly interesting footnote. BlackRock added 3.2m shares in the most recent reported period, taking its stake to just under 5m. State Street added 1.1m. T. Rowe Price and Vanguard both built positions in Q1. The parent entity ULSE Inc. retains a controlling 61.5% stake and trimmed 14.4m shares in the December quarter — a significant disposal, though one that leaves control firmly in place. Insider activity around May 1 involved several C-suite awards and a handful of small open-market sells by division-level executives at $91.60, well below the current price. The net 90-day insider position across all transactions is modestly positive at around 101,000 shares net bought.
A second earnings event is now confirmed for May 20 — likely an investor day or supplemental release. With the stock trading above the analyst consensus target and options still carrying a heavy put skew, the question heading into that date is less about whether the business is growing and more about whether management's guidance frame can absorb the valuation premium the market has now assigned.
See the live data behind this article on ORTEX.
Open ULS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
